What mistakes do sponsors make when choosing a CDMO to run “first in human” (FIH) clinical trials?
Sponsors often run into avoidable problems when CDMO contracts don’t clearly address how the product must be controlled for early-in-human risk. Common pitfalls include vague scope for GMP manufacturing versus “clinical supply” responsibilities, unclear expectations for analytics/EM (electronic records) readiness, and incomplete alignment on stability, packaging, labeling, and release testing requirements.
Typical contract gaps that lead to delays or compliance issues are:
- Not specifying the manufacturing batch record (and change-control) expectations for FIH material, including how deviations are handled and documented.
- Not defining which party owns analytical method readiness for phase-appropriate specifications (especially for trace impurities and characterization work often needed in FIH).
- Underestimating the operational requirements for clinical packaging, labeling, and distribution-to-trial-site logistics (which can be as critical as the drug substance/drug product itself).
- Failing to set clear timelines for release testing and disposition decisions, which can bottleneck dosing start dates.
What contract terms most often cause schedule slips in FIH clinical manufacturing?
FIH programs are unforgiving when critical path items are not locked early. Schedule slippage commonly comes from contract language that leaves key decision points undefined or late.
Common pitfalls tied to timing include:
- Ambiguous “lead time” for materials/inputs. For FIH, you can’t assume long-standing commercial lead times will apply.
- No clear service levels for review/approval turnaround (e.g., how quickly the sponsor reviews batch records, CoAs, deviation reports, and labeling artwork).
- Weak rules around transfer of data and documents (e.g., method files, validation packages, stability protocols). If these aren’t scheduled and scoped, they become churn later.
- Not stating what happens if the sponsor provides incomplete inputs (API characterization, formulation guidance, labeling text, protocol specifications). Without a contract mechanism, the CDMO may proceed conservatively and still miss dates.
What quality/compliance pitfalls show up most often in FIH CDMO contracts?
FIH material often requires additional scrutiny because patient exposure risk is higher and the product is frequently less “mature” than later-phase offerings. Contracts that don’t explicitly require the right quality system artifacts create avoidable inspection and release risks.
Pitfalls include:
- Not defining the quality unit’s responsibilities and approval authorities for deviations, OOS/OOT investigations, and change controls.
- Omitting requirements for data integrity controls (ALCOA+), electronic systems readiness, and audit trail access for sponsor oversight.
- Not specifying expectations for GMP documentation completeness (e.g., how comprehensive the batch record must be, what goes into the “release package,” and whether raw data review is required).
- Not addressing how residual risk is handled when FIH specs are still evolving (e.g., characterization limits versus release limits).
What goes wrong in tech transfer clauses for first-in-human supplies?
Tech transfer is a frequent failure point because FIH timelines leave little room for rework. Contracts that don’t fully define responsibilities can turn transfer into a moving target.
Common pitfalls:
- Not locking the “source” process and documentation package early (instead of waiting for late-cycle iterations).
- Failing to specify what constitutes a completed tech transfer: method suitability, process parameter lock, comparability data expectations, and readiness to run.
- No agreement on who pays for iteration (additional runs, added characterization, extra stability time, re-validation steps).
- Not defining how supplier/manufacturing changes (materials, equipment, subcontractors) will be assessed for impact on the FIH product.
How do unclear responsibilities around analytical testing cause problems?
FIH release is frequently dominated by analytical readiness and data package completeness. Contract ambiguity around analytics can lead to late CoA issuance and dosing delays.
Common pitfalls:
- Not defining which assays are required for release versus characterization, and by when.
- No explicit method transfer plan (who transfers, who verifies, and what acceptance criteria are used).
- Not specifying whether the CDMO must deliver validated methods or “method-ready” methods suitable for the intended release strategy.
- Not establishing data deliverables (raw data versus reviewed results, certificates, reference standards documentation, calibration records).
Can the contract avoid labeling, packaging, and distribution bottlenecks?
Yes—many FIH delays originate from labeling and clinical logistics that were treated as “standard” rather than time-critical.
Pitfalls:
- Labeling/packaging scope not tied to protocol-specific requirements (and not scheduled to match site needs).
- No clear ownership for handling last-minute changes in kit configuration, language requirements, or site-specific instructions.
- Not defining distribution responsibilities (temperature excursions handling, chain-of-custody expectations, destruction/return procedures).
What are the pricing and liability pitfalls that hurt FIH timelines?
Budget disputes also slow FIH programs when contracts don’t provide predictable cost and change mechanisms.
Common pitfalls:
- Fixed price without clear exclusions for deviation investigations, additional characterization, rework, or extra release testing.
- Missing change-control pricing and timeline rules (how quickly changes must be priced/approved).
- No clear liability allocation for late inputs from sponsor versus CDMO execution risks.
- Payment terms that don’t match deliverables (e.g., pay milestones before critical documents are accepted, or without acceptance criteria).
How should sponsors handle change control when FIH specs evolve midstream?
FIH programs can require tightening or adjusting specifications as characterization data accumulates. Contracts that only describe “one set of specs” without a path for controlled evolution create either delays or disputes.
Pitfalls:
- Not defining “what triggers” spec updates and how those updates affect qualification/validation status.
- No plan for re-testing old material versus only testing new lots.
- Not specifying whether updates require additional comparative analysis and who pays.
What “gotchas” appear in subcontracting and oversight?
For FIH, subcontracting can be necessary but can also add complexity and gaps if oversight isn’t contracted tightly.
Pitfalls:
- Sponsor oversight rights not clearly defined (audit frequency, documentation access, right to review quality agreements).
- No clear chain-of-custody and responsibility for deviations at subcontractor sites.
- Not requiring that subcontractors follow the same data integrity and quality requirements.
What should be in an FIH CDMO contract to avoid these pitfalls?
The contract should be explicit about scope, quality responsibilities, timelines, deliverables, acceptance criteria, and change-control mechanics. In practice, sponsors aim to define:
- Manufacturing and analytical deliverables for both DS and DP (if applicable), including release package contents
- Deviation/change-control roles and documentation expectations
- Analytical method responsibility and deliverable format (including raw data or reviewed results)
- Labeling, packaging, stability, and distribution responsibilities tied to clinical-site needs
- Tech transfer definitions that mark “ready to manufacture”
- Clear schedule interfaces (sponsor review windows, CDMO turnaround SLAs)
- Pricing rules for iteration, re-testing, additional runs, and method/spec updates
If you share whether the FIH material is DS, DP, or both, and whether you’re contracting for method development/validation versus only manufacturing, I can tailor a “pitfall checklist” to the exact CDMO scope you’re negotiating.